Hoverink Biotechnologies, Inc., today announced Hoverink CEO Debbie Carter Steps Down; Cyrus Sajna Appointed as her Successor
January 23, 2020 14:45 ET
|
Hoverink Biotechnologies, Inc
Los Angeles, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Hoverink Biotechnologies announced today that CEO Debbie Mae Carter will step down and will be succeeded by Cyrus Sajna as CEO and CFO of the company. ...
BODY GLOBE BODY ARMOR® COMPLETES LEVEL II BALLISTICS TEST HOVERINK BIOTECHNOLOGIES ANNOUNCES THEY ARE NOW TAKING PRE-SALE ORDERS
April 02, 2019 17:03 ET
|
Hoverink Biotechnologies, Inc
LOS ANGELES, CA, April 02, 2019 (GLOBE NEWSWIRE) -- Hoverink Biotechnologies, Inc announced today that on February 28, 2019, HP White concluded its level II ballistics test for the U.S. Patent...
Hoverink Biotechnologies, Inc., today announced that they have completed an application with the USPTO for MAXKAFLEN®. Hoverink Biotechnologies, Inc plans to develop and commercialize MAXKAFLEN® a cattle and swine antibiotic.
November 12, 2018 14:30 ET
|
Hoverink Biotechnologies, Inc
Overview LOS ANGELES, CA, Nov. 12, 2018 (GLOBE NEWSWIRE) -- On September 26, 2018 We filed trademark applications covering: MAXKAFLEN® Word Mark MAXKAFLEN Goods and Services IC 005....
Hoverink Biotechnologies, Inc., today announced that they have completed an application with the USPTO for KAIYADRU®. Hoverink Biotechnologies, Inc plans to develop and commercialize KAIYADRU®
November 09, 2018 18:42 ET
|
Hoverink Biotechnologies, Inc
Overview On September 26, 2018 We filed trademark applications covering: LOS ANGELES, CA, Nov. 09, 2018 (GLOBE NEWSWIRE) -- KAIYADRU® Pharmaceutical preparations, namely,...
HOVERINK BIOTECHNOLOGIES APPOINTS VSTOCK TRANSFER, LLC AS ITS TRANSFER AGENT AND REGISTRAR
July 11, 2018 10:24 ET
|
Hoverink Biotechnologies, Inc
LOS ANGELES, CA, July 11, 2018 (GLOBE NEWSWIRE) -- HOVERINK BIOTECHNOLOGIES Appoints VSTOCK TRANSFER, LLC as its TRANSFER AGENT AND REGISTRAR Hoverink Biotechnologies is currently developing IV and...
LADAVRU® NEWS “HOVERINK BIOTECHNOLOGIES SEEKS COMMERCIAL PARTNERING OPPORTUNITIES IN ONCOLOGY SUPPORTIVE THERAPIES AND SEEKS A COMMERCIALIZATION AGREEMENT FOR ITS INVESTIGATIONAL DRUG LADAVRU®”
July 05, 2018 19:20 ET
|
Hoverink Biotechnologies, Inc
LOS ANGELES, CA, July 05, 2018 (GLOBE NEWSWIRE) -- HOVERINK BIOTECHNOLOGIES, seeks to enter into a licensing agreement for the exclusive rights to commercialize LADAVRU(TM) (Dronabinol for...
BODY GLOBE BODY ARMOR® RECEIVES NOTICE OF ALLOWANCE (NOA) NOTICE FROM THE UNITED STATES PATENT AND TRADEMARK OFFICE (USPTO) HOVERINK BIOTECHNOLOGIES ANNOUNCES.
May 25, 2018 21:01 ET
|
Hoverink Biotechnologies, Inc
LOS ANGELES, CA, May 25, 2018 (GLOBE NEWSWIRE) -- Hoverink Biotechnologies, Inc announced today it has received its NOTICE OF ALLOWANCE (NOA) from the UNITED STATES PATENT AND TRADEMARK OFFICE for...
LADAVRU® RECEIVES APPROVED FOR PUBLICATON NOTICE FROM THE UNITED STATES PATENT AND TRADEMARK OFFICE (USPTO) HOVERINK BIOTECHNOLOGIES ANNOUNCES.
April 29, 2018 18:53 ET
|
Hoverink Biotechnologies, Inc
LOS ANGELES, CA, April 29, 2018 (GLOBE NEWSWIRE) -- Hoverink Biotechnologies, Inc announced today it has received its Notice of publication from the UNITED STATES PATENT AND TRADEMARK OFFICE for...
HOVERINK BIOTECHNOLOGIES INITIATES PRIVATE PLACEMENT OF CONVERTIBLE NOTES
April 27, 2018 21:22 ET
|
Hoverink Biotechnologies, Inc
LOS ANGELES, CA, April 27, 2018 (GLOBE NEWSWIRE) -- Hoverink Biotechnologies, Inc announced today it intends to offer, subject to market and other conditions, $2.5 million of Series A Convertible...